- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
RFX1 Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP16766b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP16766b-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
RFX1 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | P22670 |
| Other Accession | P48377, NP_002909.4 |
| Reactivity | Human |
| Predicted | Mouse |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 104758 Da |
RFX1 Antibody (C-term) - Additional info | |
| Gene ID 5989 | |
| Other Names RFX1; MHC class II regulatory factor RFX1; Enhancer factor C; Regulatory factor X 1; Transcription factor RFX1 | |
| Target/Specificity This RFX1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 895-925 amino acids from the C-terminal region of human RFX1. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions RFX1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
RFX1 Antibody (C-term) - Protein Information | |
| Name RFX1 | |
| Function Regulatory factor essential for MHC class II genes expression. Binds to the X boxes of MHC class II genes. Also binds to an inverted repeat (ENH1) required for hepatitis B virus genes expression and to the most upstream element (alpha) of the RPL30 promoter | |
| Cellular Location Nucleus. | |
RFX1 Antibody (C-term) - Related products
RFX1 Antibody (C-term) - Application data
-
RFX1 Antibody (C-term) (Cat. #AP16766b) western blot analysis in ZR-75-1 cell line lysates (35ug/lane).This demonstrates the RFX1 antibody detected the RFX1 protein (arrow).
RFX1 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene is a member of the regulatory factor X gene family, which encodes transcription factors that contain a highly-conserved winged helix DNA binding domain. The protein encoded by this gene is structurally related to regulatory factors X2, X3, X4, and X5. It is a transcriptional activator that can bind DNA as a monomer or as a heterodimer with RFX family members X2, X3, and X5, but not with X4. This protein binds to the X-boxes of MHC class II genes and is essential for their expression. Also, it can bind to an inverted repeat that is required for expression of hepatitis B virus genes.
REFERENCES
Zhao, M., et al. J. Autoimmun. 35(1):58-69(2010) Purvis, T.L., et al. Gene 460 (1-2), 20-29 (2010) : Hsu, Y.C., et al. J. Biol. Chem. 285(18):13885-13895(2010) Seguin-Estevez, Q., et al. J. Immunol. 183(4):2545-2553(2009) Zhang, Y., et al. Mol. Biol. (Mosk.) 43(1):77-84(2009)